Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: A new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II)

YASUHIRO OGAWA1, KEI KUBOTA1, HIRONOBU UE1, YUKO KATAOKA1, MICHIKO TADOKORO1, KANA MIYATAKE1, KAZUHIRO TSUZUKI1, TOMOAKI YAMANISHI1, SATOSHI ITOH1, JIRO HITOMI1, NORIHIKO HAMADA1, SHINJI KARIYA1, MITSUTAKA FUKUMOTO1, AKIHITO NISHIOKA1 and TAISUKE INOMATA2

1Department of Diagnostic Radiology and Radiation Oncology, Medical School, Kochi University, Kochi 783-8505; 2Department of Radiology, Osaka Medical College, Osaka 569-8686, Japan

Received October 23, 2008; Accepted November 27, 2008

DOI: 10.3892/ijo_00000186

Abstract. Using a currently employed linear accelerator, our intent was to inactivate peroxidase/catalase in tumor tissue by the application of hydrogen peroxide, which is degraded to produce oxygen, thus re-oxygenizing the tumor tissue. In this way, we can convert radioresistant tumors into radiosensitive ones. On the basis of this strategy, we previously developed a new enzyme-targeting radiosensitization treatment named KORTUC I, which remarkably enhances the radiotherapeutic effect on various types of superficially exposed and locally advanced malignant neoplasms. Based on our clinical experience using KORTUC I, we also developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for injection into various types of tumors that are not superficially exposed (KORTUC II; described herein). KORTUC II was approved by our local ethics committee for advanced skin cancer, including malignant melanoma, bone/soft tissue malignant neoplasms, breast cancer, and metastatic lymph nodes. A maximum of 6 ml of the agent was injected into tumor tissue one to two times per week under ultrasonographic guidance, just prior to each administration of radiation therapy. Eleven patients, including seven with breast cancer, were enrolled in the KORTUC II trial upon fully informed consent. KORTUC II was well tolerated, with a minimum of adverse effects. Nine of the 11 patients showed a complete response (CR), and no severe complications occurred in any of the 11 patients. This new enzyme-targeting radiosensitization treatment may be indicated for various types of locally advanced neoplasms, including soft tissue neoplasms and breast cancers.

Introduction

During radiotherapy delivered by a linear accelerator (Linac) in current use, our intent was to inactivate peroxidase/catalase in tumor tissue by the application of hydrogen peroxide, thus re-oxygenizing the tumor tissue with the oxygen produced by the degradation of hydrogen peroxide. We have previously shown that a low dose of hydrogen peroxide can cause radiation-induced apoptosis in a radioresistant osteosarcoma cell line, HS-Os-1, demonstrating that hydrogen peroxide has strong activity as a new radiosensitizer (1-3). In this way, we can convert radioresistant tumors into radiosensitive ones. On the basis of our experimental results, we have developed a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type I (KORTUC I). This remarkably enhances the radiotherapeutic effect on various types of superficially exposed and locally advanced malignant tumors including soft tissue neoplasms and breast cancers, as described previously (4). In the KORTUC I method, the surface of the tumor is covered by 3% hydrogen peroxide solution (Oxydol)-soaked gauze during each administration of radiation therapy. Based on our clinical experiences using KORTUC I, we went on to develop a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for injection into various types of tumors that are not superficially exposed. The concepts underlying this new enzyme-targeting radiosensitization treatment, KORTUC II, are shown...
The goal of the present study was to ascertain the feasibility and tolerability of our new approach.

**Materials and methods**

In the present study, we describe KORTUC II radiosensitization therapy using a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate. This was used in injection of several types of tumor: locally advanced skin cancer including malignant melanoma, bone/soft tissue tumor, breast cancer, and metastatic lymph nodes, as approved by our local ethics committee. In contrast to our previous method utilizing Oxydol-soaked gauze, the present method requires the injection of hydrogen peroxide directly into the non-superficially exposed tumor. Prior to clinical application, we performed experimental studies to ascertain safety of the method (5). Since hydrogen peroxide is an irritant that may cause severe adverse effects, we developed a new hydrogen peroxide-containing radiosensitizer that is safe for injection, effectively conferring radiosensitivity while avoiding irritation of the local tissue. This was achieved through the addition of sodium hyaluronate, which makes the solution more viscous and slows the degradation of hydrogen peroxide, allowing long-acting radiosensitization of the local tumor tissue (5). Preservation of high oxygen concentration in tumor tissue for >24 h was experimentally confirmed by intratumoral injection of the agent (unpublished data).

**Preparation of the radiosensitizing agent.** The radiosensitizing agent is composed of 0.83% sodium hyaluronate and 0.5% hydrogen peroxide. It is currently prepared by adding 0.5 ml of 3% hydrogen peroxide solution (Oxydol, Ken-ei Pharmaceutical Co. Ltd., Osaka, Japan) into a commercially available disposable syringe containing 2.5 ml of 1.0% sodium hyaluronate, which is ordinarily used for intra-articular injection in chronic knee joint disorders. Hydrogen peroxide is added just before use in order to avoid the degradation of sodium hyaluronate by the oxidative effect of hydrogen peroxide.

**Patient selection and radiotherapy.** Eleven patients, including seven with breast cancer, were enrolled in the KORTUC II trial upon fully informed consent, and each patient signed an informed consent form before joining the study. Patient data are summarized in Tables I and II. Patients were eligible for this study if they had locally advanced and/or recurrent malignant neoplasms or contraindications to general anesthesia due to significant comorbidity, or if they had declined surgical treatment.

For these patients, radiation therapy with high-energy X-ray was delivered with an EXL-20TP linear accelerator equipped with a multi-leaf collimator (Mitsubishi Electric Co. Ltd., Tokyo, Japan) at an appropriate energy level (4, 6, or 10 MV) depending on the depth of each lesion. For patients with breast cancer, hypofraction radiotherapy was given using a tangential field approach; energy level was 4 MV, total radiation therapy dose was 44 Gy, administered as 2.75 Gy/fraction (6,7). For those with cancers other than breast cancer, total dose was 60 Gy, with each fraction size being 2 Gy. Radiation therapy was performed five times a week for each patient. After starting radiotherapy, intratumoral injection of our new radiosensitizer was performed under ultrasonographic guidance twice a week for two weeks, and then once a week thereafter, just prior to radiation therapy. A maximum of 6 ml of the agent was injected.

**Patient assessment.** Tumor response was assessed according to the RECIST criteria (8), and patient monitoring and tumor assessment were carried out at regular intervals of once a month. Patients were assigned a toxicity grade from a standard assessment scale (NIH common toxicity criteria). Treatment-related complications were assessed in detail to evaluate the feasibility of this approach. These patients were followed-up for >12 months.
Table I. Summarized data for the patients treated with KORTUC II.

<table>
<thead>
<tr>
<th>Case</th>
<th>Disease</th>
<th>Age/sex</th>
<th>Therapeutic effect</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Locally advanced breast cancer (multi-drug resistant)</td>
<td>58/F</td>
<td>CR (op. performed after 3 months)</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>2</td>
<td>Malignant fibrous histiocytoma (recurrent, left thigh)</td>
<td>91/M</td>
<td>CR for 6 months (injection site)</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>3</td>
<td>Malignant schwannoma (recurrent, rt. foot)</td>
<td>73/F</td>
<td>NC (stable disease) for 6 months</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>4</td>
<td>Fibrosarcoma (recurrent, rt. thigh)</td>
<td>75/F</td>
<td>CR for 5 months</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>5</td>
<td>Breast cancer (T2N0)</td>
<td>88/F</td>
<td>CR for &gt;15 months. Now, NEDa</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>6</td>
<td>Breast cancer (T2N0) + heart failure + allergy</td>
<td>78/F</td>
<td>CR for &gt;14 months Now, NEDa</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>7</td>
<td>Bilateral breast cancer (lt.:T2N0, rt.:T1cN0)</td>
<td>79/F</td>
<td>Both sides: CR for &gt;12 months Now, NEDa</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>8</td>
<td>Breast cancer (T2N0, lt. E region, op. refused)</td>
<td>59/F</td>
<td>CR for &gt;11 months Now, NEDa</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>9</td>
<td>Breast cancer (T1cN0)</td>
<td>77/F</td>
<td>CR for 11 months Now, NEDa</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>10</td>
<td>Primary lesion of breast cancer (stage IV)</td>
<td>63/F</td>
<td>CR for 10 months</td>
<td>Mild dermatitis, grade I</td>
</tr>
<tr>
<td>11</td>
<td>Huge sized-metastatic lymph nodes of rt. neck (SCC)</td>
<td>57/M</td>
<td>Good PR for 5 months</td>
<td>Mild dermatitis, grade I</td>
</tr>
</tbody>
</table>

aNED, no evidence of disease.

Table II. Adverse events that occurred in the study

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Adverse event</th>
<th>Duration (day)</th>
<th>Severity</th>
<th>Cause</th>
<th>Action</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Local pain</td>
<td>2</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
<tr>
<td>3</td>
<td>Local pain</td>
<td>3</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
<tr>
<td>4</td>
<td>Local pain</td>
<td>1</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
<tr>
<td>7</td>
<td>Local pain</td>
<td>1</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
<tr>
<td>8</td>
<td>Local pain</td>
<td>1</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
<tr>
<td>11</td>
<td>Local pain</td>
<td>1</td>
<td>Mild</td>
<td>Injection</td>
<td>None</td>
<td>Resolved</td>
</tr>
</tbody>
</table>

Results

Patient data are summarized in Table I. Eleven patients, including with breast cancer, were enrolled in the KORTUC II trial upon fully informed consent. Nine patients achieved complete response (CR), one showed partial response (PR), and the other had no change (NC). Six of the patients with CR had breast cancer and were unable or unwilling to
undergo surgery and therefore undertook non-surgical breast-conservation treatment. These patients have so far shown neither local recurrence nor distant metastasis. Of the 3 remaining patients with CR, one had chemotherapy-resistant giant axillary and supraclavicular lymph node metastases of breast cancer, one had recurrent malignant fibrous histiocytoma...

Figure 2. Evidence of the therapeutic effects of KORTUC II for a patient with recurrent and unresectable malignant fibrous histiocytoma (case 2). Tumor blood flow gradually decreased and almost disappeared with continued radiation therapy using presensitization with intratumoral injection of the new agent.

Figure 3. A patient with giant chemotherapy-resistant metastatic lymphadenopathy secondary to breast cancer (case 1).
(MFH), and the other had recurrent fibrous sarcoma. The patient with PR had giant metastatic lymphadenopathy of the neck. The tumor that exhibited NC was a large recurrent malignant schwannoma on the right foot.

Adverse events are described in detail in Table II. Six patients experienced minor adverse events; all were mild local pain at the injection site. For all 11 patients, radiation-induced dermatitis was mild (Grade I, Table I) and equivalent to that observed at our facility after radiation therapy alone.

In patients who responded, the therapeutic effects of KORTUC II have continued, on average, for >12 months. Representative cases are shown in Figs. 2-11.

Discussion

We have reported previously (4) on a highly effective radiosensitization method (KORTUC I) using 3% hydrogen peroxide solution (Oxydol)-soaked gauze for patients with superficially exposed and unresectable neoplasms. Since many patients have non-superficially exposed neoplasms such as locally advanced breast cancer, recurrent hepatocellular carcinoma, and unresectable pancreatic cancer, the development of a new radiosensitizer for tumor injection is considered to be of utmost importance. We have developed a radiosensitizer that can be safely injected into human tumor tissue under ultrasonographic guidance, and we herein report on the clinical application of this new radiosensitization treatment (KORTUC II).

Currently, most radiation therapy is performed using X-rays or high-energy electron beams from a linear accelerator; however, these forms of radiation are not ideal in terms of their low-linear energy transfer (LET) characteristics. Almost two-thirds of the radiation-induced damage to cancer cells caused by these low-LET beams is brought about by the production of reactive oxygen species (ROS) in irradiated cells (9). Therefore, oxygen is essential for oxidizing the radicals produced by irradiation. In contrast, anti-oxidative enzymes such as peroxidase/catalase scavenge radicals produced by irradiation, resulting in a decreased irradiation effect. Peroxidase/catalase is present in most tumor tissues, as demonstrated by the fact that intrinsic peroxidase must be blocked before immunohistochemical staining of tumor tissue (10,11).

To overcome the disadvantages of these low-LET beams, carbon ion beam radiotherapy has been developed. This form of radiotherapy uses high-LET beams and improves local control, resulting in better survival for patients with unresectable osteosarcoma (12). However, as constructing carbon beam facilities is extremely expensive, there is an urgent need for chemical alternatives that transform radioresistant tumors into radiosensitive ones in response to low LET radiation.

Among the numerous types of human cells, peripheral T cells are considered to be representative as regards their high level of radiosensitivity (13,14). Because human peripheral T cells lack peroxidase activity, these cells are easily...
susceptible to oxidative stress such as that caused by ROS, including hydrogen peroxide (15,16). Therefore, when T cells are irradiated, hydrogen peroxide produced by reactive oxygen species accumulates in the cytoplasm of lymphocytes and then moves into the lysosomes resulting in lysosomal membrane dysfunction causing apoptosis (17,18). In contrast, osteosarcoma cells are well known to be highly resistant to low-LET radiation, and we demonstrated by peroxidase staining that these cells contain abundant peroxidase (3). By adding low concentrations of hydrogen peroxide to the medium of the osteosarcoma cell line, these cells are easily converted to a highly radiosensitive state (2).

Although various methods of radiosensitizing treatment for radioresistant neoplasms have been developed (19-23),
a clinically applicable method has yet to be established. Many studies have been performed to increase tissue oxygen concentrations to promote the oxidation of radicals produced by low-LET irradiation to cancer cells/tissues, and few therapeutic gains have thus far been observed (24-26). Besides increasing tissue oxygen concentrations, it is considered important to inactivate anti-oxidative enzymes such as peroxidase/catalase. Hydrogen peroxide is the only agent that both inactivates anti-oxidative enzymes and produces oxygen in topical tumor tissue.
When treating low-LET radioresistant tumors, it is therefore necessary to develop a new method that both inactivates antioxidative enzymes and produces oxygen in tumor tissue in order to augment the effects of X-rays and high-energy electron beams. Tumors that might be amenable to such an approach include malignant melanoma, malignant fibrous histiocytoma (MFH), various types of sarcoma, and most of the relatively large neoplasms (more than several centimeters in diameter) that are frequently seen in daily clinical oncology practice.

Previous studies have demonstrated the ability of hydrogen peroxide to induce apoptosis in numerous types of cells...
Hydrogen peroxide is a simple molecule but it has been shown to play an important role in intracellular signal transduction mechanisms. Downstream signaling events that are modulated by hydrogen peroxide include calcium mobilization, protein phosphorylation, and gene expression. Excess amounts of exogenous hydrogen peroxide are considered to have rapid and potentially disastrous effects on the ability of individual cells to scavenge ROS. In addition, exogenous hydrogen peroxide can increase intracellular hydrogen peroxide accumulation and activate MAPK (mitogen-activated protein kinase) pathways, possibly resulting in mitochondrial dysfunction and amplification of the oxidative death cycle.

In the late 1960s and early 1970s, several studies investigated the use of hydrogen peroxide in radiotherapy. The majority of reports describe intra-arterial infusions of hydrogen peroxide during radiotherapy. This line of investigation appears to have been discontinued because of difficulties with this method of delivering hydrogen peroxide, as well as lack of improved efficacy. For example, in the technique of Mallams et al., 250 ml of 0.12% hydrogen peroxide was perfused intra-arterially in about thirty minutes. Regarding intratumoral hydrogen peroxide injection, 3-5 ml of 3% hydrogen peroxide solution (Oxydol) was administered for meningioma with no significant side effects. Our method, KORTUC II, uses only 3-6 ml of 0.5% hydrogen peroxide for tumor injection, hence our dose of hydrogen peroxide was much lower than those given in the two methods described above. Moreover, the combined use of sodium hyaluronate and hydrogen peroxide in our study, KORTUC II, is considered to be a safe method based on the above-mentioned facts and our experimental results already reported.

KORTUC II represents a novel form of treatment using a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for tumor injection under ultrasonographic guidance. Patients who might benefit include those with locally advanced breast cancer, advanced skin cancer, or metastatic lymph nodes. The treatment was well tolerated, with a minimum of adverse effects such as local pain at the injection site. However, evidence of radiosensitization was demonstrated in only two cases (cases 1 and 4) in terms of comparison of KORTUC II-treated lesions with those treated by radiotherapy alone, and further study is needed to confirm the radiosensitization effect of KORTUC II.

In conclusion, the new radiosensitizer for topical tumor injection contains only hydrogen peroxide and sodium hyaluronate, substances considered not to cause severe adverse effects because they are degraded into water and oxygen in the presence of peroxidase/catalase. The method is targeted at intrinsic peroxidase/catalase present in tumor cells, infiltrating granulocytes, and contaminating red blood cells in the tumor tissue, and the agent is injected into the target tumor tissue under ultrasonographic guidance. Therefore, the method is considered to be a new enzyme-targeting radiosensitization treatment with potential indication for various types of low LET-radioresistant neoplasms. Based on our experimental data, it can be concluded that hydrogen peroxide is a radiation sensitizer. Moreover, the present study showed that the present...
formulation can be delivered safely under the conditions used in this study.

Acknowledgements

The authors would like to thank Mr. Norikazu Yokota, Mr. Toshikazu Sasaki, Mr. Akira Suzuki, Ms. Shiko Tokuhito, and Ms. Maiko Shinagawa for their assistance with this work. This study was presented at the 100th Anniversary of Tohoku University, the 5th Japan-US Cancer Therapy Symposium, and 5th S. Takahashi Memorial International Joint Symposium - Improving Therapeutic Ratio with Radiation and Molecular Targeted Treatment - held in Sendai, Japan, September 2007.

References


